Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine

S. I. Chu; H. J. Kim; K. M. Skubitz

doi:10.1097/00001813-199506000-00018

Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine

Research output: Contribution to journal › Article › peer-review

Abstract

This report describes a patient who developed pulmonary toxicity, manifest by dyspnea on exertion, a low pO₂, a normal FEV₁ and FVC, and a low DLCO while receiving 5-fluoro-2'-deoxyuridine (FUDR) by intermittent continuous i.v. infusion. No other cause of his low DLCO could be identified. The dyspnea on exertion and DLCO improved gradually after the FUDR was discontinued. This case was felt to represent a previously undescribed toxicity of the continuous i.v. infusion of FUDR.

Original language	English (US)
Pages (from-to)	475-478
Number of pages	4
Journal	Anti-Cancer Drugs
Volume	6
Issue number	3
DOIs	https://doi.org/10.1097/00001813-199506000-00018
State	Published - Jan 1 1995

Keywords

5-fluoro-2'-deoxyuridine
chemotherapy
infusional y toxicity
renal cell cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/00001813-199506000-00018

Find It

Find It at U of M Libraries

Cite this

@article{fb99dd55be694b3299be6d00e9db698f,

title = "Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine",

abstract = "This report describes a patient who developed pulmonary toxicity, manifest by dyspnea on exertion, a low pO2, a normal FEV1 and FVC, and a low DLCO while receiving 5-fluoro-2'-deoxyuridine (FUDR) by intermittent continuous i.v. infusion. No other cause of his low DLCO could be identified. The dyspnea on exertion and DLCO improved gradually after the FUDR was discontinued. This case was felt to represent a previously undescribed toxicity of the continuous i.v. infusion of FUDR.",

keywords = "5-fluoro-2'-deoxyuridine, chemotherapy, infusional y toxicity, renal cell cancer",

author = "Chu, {S. I.} and Kim, {H. J.} and Skubitz, {K. M.}",

year = "1995",

month = jan,

day = "1",

doi = "10.1097/00001813-199506000-00018",

language = "English (US)",

volume = "6",

pages = "475--478",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine

AU - Chu, S. I.

AU - Kim, H. J.

AU - Skubitz, K. M.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - This report describes a patient who developed pulmonary toxicity, manifest by dyspnea on exertion, a low pO2, a normal FEV1 and FVC, and a low DLCO while receiving 5-fluoro-2'-deoxyuridine (FUDR) by intermittent continuous i.v. infusion. No other cause of his low DLCO could be identified. The dyspnea on exertion and DLCO improved gradually after the FUDR was discontinued. This case was felt to represent a previously undescribed toxicity of the continuous i.v. infusion of FUDR.

AB - This report describes a patient who developed pulmonary toxicity, manifest by dyspnea on exertion, a low pO2, a normal FEV1 and FVC, and a low DLCO while receiving 5-fluoro-2'-deoxyuridine (FUDR) by intermittent continuous i.v. infusion. No other cause of his low DLCO could be identified. The dyspnea on exertion and DLCO improved gradually after the FUDR was discontinued. This case was felt to represent a previously undescribed toxicity of the continuous i.v. infusion of FUDR.

KW - 5-fluoro-2'-deoxyuridine

KW - chemotherapy

KW - infusional y toxicity

KW - renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0029064133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029064133&partnerID=8YFLogxK

U2 - 10.1097/00001813-199506000-00018

DO - 10.1097/00001813-199506000-00018

M3 - Article

C2 - 7670148

AN - SCOPUS:0029064133

SN - 0959-4973

VL - 6

SP - 475

EP - 478

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 3

ER -

Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine

Abstract

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this